WASHINGTON, April 9, 2018 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced
participation at the 2018 Georg Rajka International Symposium of
Atopic Dermatitis (ISAD 2018) in Utrecht,
Netherlands in the scientific poster forum on Thursday, April 12, 2018. The following
tradipitant scientific posters will be presented:
Abstract P067: "Tradipitant improves worst itch and disease
severity in patients with atopic dermatitis."
Abstract P068: "Differential effect size of tradipitant in
atopic dermatitis according to baseline IgE levels."
Abstract P069: "Tradipitant demonstrates improvements in the
patient benefit index in atopic dermatitis."
For more information on ISAD 2018, please refer to
http://isad2018.org/isad/.
About Atopic Dermatitis and Chronic Pruritus
Atopic dermatitis is a chronic, relapsing inflammatory skin
disorder characterized by the symptom of intense and persistent
pruritus or itch. Other clinical features include erythema,
excoriation, edema, lichenification, oozing and xerosis.
Atopic dermatitis is a common skin disorder affecting millions
of people worldwide. Currently there are very few safe systemic
treatments available for atopic dermatitis, representing a
significant unmet medical need in this population.
About the Neurokinin-1 Receptor and Substance P
The Neurokinin-1 Receptor (NK-1R) is expressed throughout
different tissues of the body, with major activity found in
neuronal tissue. Substance P (SP) and NK-1R interactions in
neuronal tissue regulate neurogenic inflammation locally and the
pain perception pathway through the central nervous system. Other
tissues, including endothelial cells and immune cells, have also
exhibited SP and NK-1R activity (2). The activation of NK-1R by the
natural ligand SP is involved in numerous physiological processes,
including the perception of pain, behavioral stressors, cravings
and the processes of nausea and vomiting (1,2,3). An inappropriate
over-expression of SP, either in nervous tissue or peripherally,
could result in pathological conditions such as substance
dependence, anxiety, nausea/vomiting and pruritus (1,2,3,4). An
NK-1R antagonist may possess the ability to reduce this
over-stimulation of the NK-1R, and as a result address the
underlying pathophysiology of the symptoms in these conditions.
About Tradipitant
Tradipitant is an NK-1R antagonist licensed by Vanda from Eli
Lilly and Company (Lilly) in 2012. Tradipitant is currently in
clinical development for atopic dermatitis and gastroparesis. The
patent describing tradipitant as a new chemical entity is expected
to expire in the United States in
June 2029 based on an anticipated
Hatch-Waxman patent term extension. Tradipitant is an
investigational drug that is not currently approved for use in any
indication.
About Vanda
Vanda is a global biopharmaceutical company focused on the
development and commercialization of innovative therapies to
address high unmet medical needs and improve the lives of
patients. For more on Vanda Pharmaceuticals Inc., please
visit www.vandapharma.com.
References
1. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C,
Peng X, Keilbasa W, Rawlings R, Brandt JE, Gehlert DR, Tauscher JT, Hunt SP, Hommer D, Heilig M.
Neurokinin 1 receptor antagonism as a possible therapy for
alcoholism. Science. 2008; 319(5869):1536-9.
2. Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, et al.
Tachykinins and tachykinin receptors: structure and activity
relationships. Current Medicinal Chemistry. 2004;11:2045-2081.
3. Hargreaves R, Ferreira JC, Hughes D, Brands J, Hale J,
Mattson B, Mill S. Development of aprepitant, the first
neurokinin-1 receptor antagonist for the prevention of
chemotherapy-induced nausea and vomiting. Annals of the New York
Academy of Sciences. 2011; 1222:40-48.
4. Staender S, Weisshaar E, Luger A. Neurophysiological and
neurochemical basis of modern pruritus treatment. Experimental
Dermatology. 2007;17:161-69.
Corporate Contact:
Jim
Kelly
Executive Vice President and Chief Financial
Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
View original
content:http://www.prnewswire.com/news-releases/vanda-to-present-tradipitant-scientific-posters-at-the-10th-georg-rajka-international-symposium-of-atopic-dermatitis-300626647.html
SOURCE Vanda Pharmaceuticals Inc.